Company: SUPN
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001356576-25-000033
Chunk: 33

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-05-06
Form: 10-Q
Item: Part I, Item 1
Chunk 33
---
Supernus Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

(in thousands, except share data)March 31,December 31,20252024(unaudited)AssetsCurrent assetsCash and cash equivalents$115,848 $69,331 Marketable securities347,742 384,281 Accounts receivable, net145,640 142,077 Inventories, net49,423 54,293 Prepaid expenses and other current assets28,931 36,088 Total current assets687,584 686,070 Property and equipment, net11,338 11,545 Intangible assets, net502,126 521,912 Goodwill117,019 117,019 Other assets29,223 31,527 Total assets$1,347,290 $1,368,073 Liabilities and stockholders’ equityCurrent liabilitiesAccounts payable and accrued liabilities$76,891 $76,352 Accrued product returns and rebates170,133 168,705 Contingent consideration, current portion30,000 47,340 Other current liabilities4,748 — Total current liabilities281,772 292,397 Operating lease liabilities, long-term26,368 27,382 Deferred income tax liabilities, net981 4,961 Other liabilities7,464 7,600 Total liabilities316,585 332,340 Commitments and contingencies (Note 15)Stockholders’ equityCommon stock, $0.001 par value; 130,000,000 shares authorized; 55,989,248 and 55,743,095 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively56 56 Additional paid-in capital486,209 479,440 Accumulated other comprehensive loss, net of tax(159)(189)Retained earnings544,599 556,426 Total stockholders’ equity1,030,705 1,035,733 Total liabilities and stockholders’ equity$1,347,290 $1,368,073 

See accompanying notes.

3

Table of Contents

Supernus Pharmaceuticals, Inc.

Condensed Consolidated Statements of Earnings (Loss)

(in thousands, except share and per share data)

Three Months EndedMarch 31,20252024(unaudited)RevenuesNet product sales$141,988